IMARC Group has recently released a report titled “Esophageal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033” that presents a comprehensive assessment of the esophageal cancer market size, latest trends, and growth forecast. The report provides an overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market scenario, and growth trends. In addition, the report offers competitor analysis, regional analysis, and recent advancements in the global market. The report also highlights key segments and market drivers, as well as challenges faced by industry players.
Esophageal cancer represents a type of cancer that occurs in the cells of the esophagus, the muscular tube that carries liquid and food from the throat to the stomach. It is mainly of two types: squamous cell carcinoma and adenocarcinoma. The symptoms include pain or discomfort in the chest or back, persistent coughing or hoarseness, unintentional weight loss, regurgitation of food or liquid, chronic hiccups, heartburn or acid reflux, vomiting, etc. The diagnosis of esophageal cancer typically involves several imaging tests, such as a PET scan, a barium swallow, a CT scan, etc., that are used to visualize the esophagus and look for signs of cancerous cells.
Request a Free Sample Report: https://www.imarcgroup.com/esophageal-cancer-market/requestsample
Market Trend:
The increasing cases of chronic inflammation of the esophagus, which can result from gastroesophageal reflux disease (GERD), are primarily augmenting the esophageal cancer market. In addition to this, the elevating prevalence of various associated risk factors, such as tobacco use, heavy alcohol consumption, obesity, etc., is further stimulating the market growth. Moreover, the rising utilization of endoscopic imaging techniques, including narrow-band imaging (NBI) and confocal laser endomicroscopy (CLE), for diagnosing esophageal cancer is acting as another significant growth-inducing factor. Besides this, the emerging popularity of multimodal approaches, which involve combining different treatment modalities, such as surgery, chemotherapy, radiation therapy, etc., to enhance outcomes for patients with esophageal cancer, is offering lucrative growth opportunities to the esophageal cancer market. Furthermore, the escalating adoption of immunotherapy, which uses the body’s immune system to fight cancer by treating certain cases of esophageal cancer caused by specific genetic mutations, is expected to bolster the esophageal cancer market in the coming years.
Report Period:
- Base Year: 2022
- Historical Period: 2017-2022
- Market Forecast: 2023-2033
Countries Included:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the esophageal cancer market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the esophageal cancer market
- Reimbursement scenario in the market
- In-market and pipeline drugs
In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Regulatory Status
Ask an Analyst for Report Customization with TOC & List of figures: https://www.imarcgroup.com/esophageal-cancer-market
Key Questions Answered in this Report:
- How has the esophageal cancer market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
- What was the country-wise size of the esophageal cancer market across the seven major markets in 2022 and what will it look like in 2033?
- What is the growth rate of the esophageal cancer market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
About Us: –
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Esophageal Cancer – Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2017-2022) and Forecast (2023-2033)
4.4 Market Overview (2017-2022) and Forecast (2023-2033)
4.5 Competitive Intelligence
5 Esophageal Cancer – Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Esophageal Cancer – Epidemiology and Patient Population
7.1 Epidemiology – Key Insights
7.2 Epidemiology Scenario – Top 7 Markets
7.2.1 Epidemiology Scenario (2017-2022)
7.2.2 Epidemiology Forecast (2023-2033)
7.2.3 Epidemiology by Age (2017-2033)
7.2.4 Epidemiology by Gender (2017-2033)
7.2.5 Epidemiology by Type (2017-2033)
7.2.6 Diagnosed Cases (2017-2033)
7.2.7 Patient Pool/Treated Cases (2017-2033)
7.3 Epidemiology Scenario – United States
7.3.1 Epidemiology Scenario (2017-2022)
7.3.2 Epidemiology Forecast (2023-2033)
7.3.3 Epidemiology by Age (2017-2033)
7.3.4 Epidemiology by Gender (2017-2033)
7.3.5 Epidemiology by Type (2017-2033)
7.3.6 Diagnosed Cases (2017-2033)
7.3.7 Patient Pool/Treated Cases (2017-2033)
7.4 Epidemiology Scenario – Germany
7.4.1 Epidemiology Scenario (2017-2022)
7.4.2 Epidemiology Forecast (2023-2033)
7.4.3 Epidemiology by Age (2017-2033)
7.4.4 Epidemiology by Gender (2017-2033)
7.4.5 Epidemiology by Type (2017-2033)
7.4.6 Diagnosed Cases (2017-2033)
7.4.7 Patient Pool/Treated Cases (2017-2033)
7.5 Epidemiology Scenario – France
7.5.1 Epidemiology Scenario (2017-2022)
7.5.2 Epidemiology Forecast (2023-2033)
7.5.3 Epidemiology by Age (2017-2033)
7.5.4 Epidemiology by Gender (2017-2033)
7.5.5 Epidemiology by Type (2017-2033)
7.5.6 Diagnosed Cases (2017-2033)
7.5.7 Patient Pool/Treated Cases (2017-2033)
7.6 Epidemiology Scenario – United Kingdom
7.6.1 Epidemiology Scenario (2017-2022)
7.6.2 Epidemiology Forecast (2023-2033)
7.6.3 Epidemiology by Age (2017-2033)
7.6.4 Epidemiology by Gender (2017-2033)
7.6.5 Epidemiology by Type (2017-2033)
7.6.6 Diagnosed Cases (2017-2033)
7.6.7 Patient Pool/Treated Cases (2017-2033)
7.7 Epidemiology Scenario – Italy
7.7.1 Epidemiology Scenario (2017-2022)
7.7.2 Epidemiology Forecast (2023-2033)
7.7.3 Epidemiology by Age (2017-2033)
7.7.4 Epidemiology by Gender (2017-2033)
7.7.5 Epidemiology by Type (2017-2033)
7.7.6 Diagnosed Cases (2017-2033)
7.7.7 Patient Pool/Treated Cases (2017-2033)
7.8 Epidemiology Scenario – Spain
7.8.1 Epidemiology Scenario (2017-2022)
7.8.2 Epidemiology Forecast (2023-2033)
7.8.3 Epidemiology by Age (2017-2033)
7.8.4 Epidemiology by Gender (2017-2033)
7.8.5 Epidemiology by Type (2017-2033)
7.8.6 Diagnosed Cases (2017-2033)
7.8.7 Patient Pool/Treated Cases (2017-2033)
7.9 Epidemiology Scenario – Japan
7.9.1 Epidemiology Scenario (2017-2022)
7.9.2 Epidemiology Forecast (2023-2033)
7.9.3 Epidemiology by Age (2017-2033)
7.9.4 Epidemiology by Gender (2017-2033)
7.9.5 Epidemiology by Type (2017-2033)
7.9.6 Diagnosed Cases (2017-2033)
7.9.7 Patient Pool/Treated Cases (2017-2033)
8 Esophageal Cancer – Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Esophageal Cancer – Unmet Needs
10 Esophageal Cancer – Key Endpoints of Treatment
11 Esophageal Cancer – Marketed Products
11.1 List of Esophageal Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Keytruda (Pembrolizumab) – Merck & Co
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Opdivo (Nivolumab) – Bristol-Myers Squibb/Ono Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Photofrin (Porfimer sodium) – Pinnacle Biologics
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 Esophageal Cancer – Pipeline Drugs
12.1 List of Esophageal Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 Tiragolumab – Genentech
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Atezolizumab – Genentech
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Zanidatamab – Zymeworks
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Ramucirumab – Eli Lilly and Company
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Tislelizumab – BeiGene
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. Esophageal Cancer – Attribute Analysis of Key Marketed and Pipeline Drugs
14. Esophageal Cancer – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Esophageal Cancer – Market Scenario
15.1 Market Scenario – Key Insights
15.2 Market Scenario – Top 7 Markets
15.2.1 Esophageal Cancer – Market Size
15.2.1.1 Market Size (2017-2022)
15.2.1.2 Market Forecast (2023-2033)
15.2.2 Esophageal Cancer – Market Size by Therapies
15.2.2.1 Market Size by Therapies (2017-2022)
15.2.2.2 Market Forecast by Therapies (2023-2033)
15.3 Market Scenario – United States
15.3.1 Esophageal Cancer – Market Size
15.3.1.1 Market Size (2017-2022)
15.3.1.2 Market Forecast (2023-2033)
15.3.2 Esophageal Cancer – Market Size by Therapies
15.3.2.1 Market Size by Therapies (2017-2022)
15.3.2.2 Market Forecast by Therapies (2023-2033)
15.3.3 Esophageal Cancer – Access and Reimbursement Overview
15.4 Market Scenario – Germany
15.4.1 Esophageal Cancer – Market Size
15.4.1.1 Market Size (2017-2022)
15.4.1.2 Market Forecast (2023-2033)
15.4.2 Esophageal Cancer – Market Size by Therapies
15.4.2.1 Market Size by Therapies (2017-2022)
15.4.2.2 Market Forecast by Therapies (2023-2033)
15.4.3 Esophageal Cancer – Access and Reimbursement Overview
15.5 Market Scenario – France
15.5.1 Esophageal Cancer – Market Size
15.5.1.1 Market Size (2017-2022)
15.5.1.2 Market Forecast (2023-2033)
15.5.2 Esophageal Cancer – Market Size by Therapies
15.5.2.1 Market Size by Therapies (2017-2022)
15.5.2.2 Market Forecast by Therapies (2023-2033)
15.5.3 Esophageal Cancer – Access and Reimbursement Overview
15.6 Market Scenario – United Kingdom
15.6.1 Esophageal Cancer – Market Size
15.6.1.1 Market Size (2017-2022)
15.6.1.2 Market Forecast (2023-2033)
15.6.2 Esophageal Cancer – Market Size by Therapies
15.6.2.1 Market Size by Therapies (2017-2022)
15.6.2.2 Market Forecast by Therapies (2023-2033)
15.6.3 Esophageal Cancer – Access and Reimbursement Overview
15.7 Market Scenario – Italy
15.7.1 Esophageal Cancer – Market Size
15.7.1.1 Market Size (2017-2022)
15.7.1.2 Market Forecast (2023-2033)
15.7.2 Esophageal Cancer – Market Size by Therapies
15.7.2.1 Market Size by Therapies (2017-2022)
15.7.2.2 Market Forecast by Therapies (2023-2033)
15.7.3 Esophageal Cancer – Access and Reimbursement Overview
15.8 Market Scenario – Spain
15.8.1 Esophageal Cancer – Market Size
15.8.1.1 Market Size (2017-2022)
15.8.1.2 Market Forecast (2023-2033)
15.8.2 Esophageal Cancer – Market Size by Therapies
15.8.2.1 Market Size by Therapies (2017-2022)
15.8.2.2 Market Forecast by Therapies (2023-2033)
15.8.3 Esophageal Cancer – Access and Reimbursement Overview
15.9 Market Scenario – Japan
15.9.1 Esophageal Cancer – Market Size
15.9.1.1 Market Size (2017-2022)
15.9.1.2 Market Forecast (2023-2033)
15.9.2 Esophageal Cancer – Market Size by Therapies
15.9.2.1 Market Size by Therapies (2017-2022)
15.9.2.2 Market Forecast by Therapies (2023-2033)
15.9.3 Esophageal Cancer – Access and Reimbursement Overview
16 Esophageal Cancer – Recent Events and Inputs From Key Opinion Leaders
17 Esophageal Cancer Market – SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Esophageal Cancer Market – Strategic Recommendations
19 Appendix